IMIC(SZ:000516)2021-04-28 16:00Financial Performance - The company's operating revenue for Q1 2021 was CNY 632,244,259.12, representing a 129.75% increase compared to the same period last year[2] - The net profit attributable to shareholders was CNY -183,074,645.82, a slight improvement of 3.35% from CNY -189,425,706.14 in the previous year[2] - The net cash flow from operating activities increased by 145.84%, reaching CNY 66,349,139.44, compared to CNY -144,746,136.11 in the same period last year[2] - Total operating revenue for Q1 2021 was CNY 632,244,259.12, a significant increase from CNY 275,182,112.80 in the same period last year, representing a growth of approximately 130%[27] - The net profit for Q1 2021 was a loss of CNY 185,159,657.65, compared to a loss of CNY 192,565,750.57 in Q1 2020, showing a slight improvement in losses[29] - The total comprehensive loss for Q1 2021 was CNY -185,159,657.65, compared to CNY -192,565,750.57 in the previous year, reflecting a reduction in overall losses[31] Assets and Liabilities - The total assets at the end of the reporting period were CNY 12,734,148,827.48, reflecting a 5.03% increase from CNY 12,124,407,681.43 at the end of the previous year[2] - The company's current assets reached CNY 2.92 billion, up from CNY 2.34 billion, indicating a growth of about 25.06% year-over-year[20] - The total liabilities decreased to CNY 6.89 billion from CNY 7.09 billion, a reduction of approximately 2.83%[22] - The equity attributable to shareholders rose to CNY 5,738,318,307.98, up from CNY 4,821,483,726.92, marking an increase of approximately 19%[26] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 76,273[5] - The largest shareholder, Shaanxi Century New Yuan Commercial Management Co., held 29.74% of the shares, amounting to 676,971,198 shares[5] - The company plans to issue up to 35,299,176 restricted shares at a price of 5.86 RMB per share to 571 incentive targets, representing 1.55% of the total share capital[9] Cash Flow and Investments - Cash and cash equivalents increased significantly to CNY 1.74 billion from CNY 1.04 billion, reflecting a growth of approximately 67.73%[20] - The total investment cash inflow amounted to ¥962,954,430.30, compared to ¥307,862,605.59 in the previous period, indicating a substantial increase of about 212.5%[37] - The company received cash from the recovery of investments totaling ¥960,000,000.00, a significant increase from ¥305,095,208.33 in the previous period[36] - Cash inflow from financing activities reached 994,339,620.08, a substantial increase from 100,000,000.00 in the previous period, indicating strong capital raising efforts[41] Operational Highlights - Operating revenue increased by 129.75% year-on-year, primarily driven by increased income from medical services[8] - The new hospital district of Shanzhou International Medical Center officially opened on March 28, 2021, enhancing the company's competitive position in the region[10] - The company raised approximately 999.99 million RMB through a private placement to support rapid development in its medical services business[14] Cost Management - Total operating costs for Q1 2021 amounted to CNY 742,690,177.83, up from CNY 474,648,969.19 in the previous year, indicating an increase of about 56%[28] - The company incurred sales expenses of ¥9,098,460.55, up from ¥8,766,621.22 in the previous period, indicating increased operational costs[32] Employee and Compensation - The company reported a decrease in employee compensation payable to CNY 85.85 million from CNY 146.06 million, a decline of about 41.14%[22] - The company paid 31,293,739.05 in employee compensation, slightly higher than 30,115,714.07 in the previous period, indicating stable workforce costs[40] Compliance and Governance - The company has no violations regarding external guarantees during the reporting period[17] - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[18] - The company did not undergo an audit for the first quarter report, which may affect the reliability of the financial data presented[42]